The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro's TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is ...

insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, ...

Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...

In collaboration with Roche, one of the world’s largest biotechnology companies, industrial technology company Emerson has developed a digital library of modalities for faster deployment and use of ...

Gene therapies promise life-saving medicines, but their uptake has been slow and recent investments in the modality and supporting technologies have lagged across the biopharmaceutical industry. Dr.

-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...

aProximate TM PTCs maintain high expression of key transporters involved in drug handling, including megalin and cubilin, making them ideal for studying drug transporters and drug interactions with ...

Fannin Partners and Allterum Therapeutics, Inc. are pleased to announce that Brian Wipke, Ph.D., an accomplished immunologist and drug discovery and development leader with more than 20 years of ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February ...